{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:13:15Z","timestamp":1787242395334,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04138-y","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T09:09:46Z","timestamp":1734944986000},"page":"1333-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET\/CT in patients with metastatic small intestine neuroendocrine tumors"],"prefix":"10.1007","volume":"87","author":[{"given":"Darejan","family":"Mamulashvili Bessac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Baltzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Poterszman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Pham Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Collen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel G.","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ouvrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashjan","family":"Kaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"Porot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Imperiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"4138_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376, 125\u2013135 (2017)","journal-title":"N Engl J Med"},{"key":"4138_CR2","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"J. Del Rivero, K. Perez, E.B. Kennedy, E.S. Mittra, N. Vijayvergia, J. Arshad et al. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol 41, 5049\u20135067 (2023)","journal-title":"J Clin Oncol"},{"key":"4138_CR3","doi-asserted-by":"crossref","unstructured":"T. Brabander, W.A. van der Zwan, J.J.M. Teunissen, B.L.R. Kam, R.A. Feelders, W.W. de Herder, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.Clin Cancer Res 23, 4617\u20134624 (2017)","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"4138_CR4","doi-asserted-by":"publisher","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","volume":"106","author":"WT Zandee","year":"2021","unstructured":"W.T. Zandee, T. Brabander, A. Bla\u017eevi\u0107, N.S. Minczeles, R.A. Feelders, W.W. de Herder et al. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. J Clin Endocrinol Metab 106, e3665\u2013e3672 (2021)","journal-title":"J Clin Endocrinol Metab"},{"key":"4138_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11154-020-09581-6","volume":"22","author":"M Albertelli","year":"2021","unstructured":"M. Albertelli, A. Dotto, C. Di Dato, P. Malandrino, R. Modica, A. Versari et al. PRRT: identikit of the perfect patient. Rev Endocr Metab Disord 22, 563\u2013579 (2021)","journal-title":"Rev Endocr Metab Disord"},{"key":"4138_CR6","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.2967\/jnumed.114.137166","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"S. Ezziddin, L. Adler, A. Sabet, T.D. P\u00f6ppel, F. Grabellus, A. Y\u00fcce et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med 55, 1260\u20131266 (2014)","journal-title":"J Nucl Med"},{"key":"4138_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"S. Ezziddin, M. Attassi, C.J. Yong-Hing, H. Ahmadzadehfar, W. Willinek, F. Gr\u00fcnwald et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 55, 183\u2013190 (2014)","journal-title":"J Nucl Med"},{"key":"4138_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.7150\/thno.51215","volume":"11","author":"D Feijtel","year":"2021","unstructured":"D. Feijtel, G.N. Doeswijk, N.S. Verkaik, J.C. Haeck, D. Chicco, C. Angotti et al. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Theranostics 11, 491\u2013505 (2021)","journal-title":"Theranostics"},{"key":"4138_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2967\/jnumed.121.262122","volume":"63","author":"G Tamborino","year":"2022","unstructured":"G. Tamborino, J. Nonnekens, M. De Saint-Hubert, L. Struelens, D. Feijtel, M. de Jong et al. Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival. J Nucl Med 63, 100\u2013107 (2022)","journal-title":"J Nucl Med"},{"key":"4138_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/PAS.0b013e31821a0696","volume":"35","author":"Z Yang","year":"2011","unstructured":"Z. Yang, L.H. Tang, D.S. Klimstra, Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver: Implications for Prognostic Stratification. American Journal of Surgical Pathology 35, 853\u2013860 (2011)","journal-title":"American Journal of Surgical Pathology"},{"key":"4138_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2967\/jnumed.123.266063","volume":"65","author":"L Al Mansour","year":"2024","unstructured":"L. Al Mansour, L. De Mestier, M. Haissaguerre, P. Afchain, J. Hadoux, T. Lecomte et al. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. J Nucl Med 65, 258\u2013263 (2024)","journal-title":"J Nucl Med"},{"key":"4138_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.242875","volume":"62","author":"JR Strosberg","year":"2021","unstructured":"J.R. Strosberg, T. Al-Toubah, E. Pell\u00e8, J. Smith, M. Haider, T. Hutchinson et al. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. J Nucl Med 62, 69\u201372 (2021)","journal-title":"J Nucl Med"},{"key":"4138_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182\u2013188 (2020)","journal-title":"Histopathology"},{"key":"4138_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00259-023-06333-x","volume":"50","author":"A Chaban","year":"2023","unstructured":"A. Chaban, J. Brosh-Lentz, Y. Song, V. Dinkel, L. Bodei, W. Weber, Optimized segmentation of neuroendocrine tumor lesions on somatostatin receptor PET\/CT imaging for therapy response assessment. EANM\u201923 Abstract Book Congress Sep 9-13, 2023. Eur J Nucl Med Mol Imaging 50, 1\u2013898 (2023). Suppl 1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4138_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2967\/jnumed.121.262782","volume":"63","author":"RP Reddy","year":"2022","unstructured":"R.P. Reddy, C. Ross Schmidtlein, R.G. Giancipoli, A. Mauguen, D. LaFontaine, H. Schoder et al. The Quest for an Accurate Functional Tumor Volume with 68Ga-DOTATATE PET\/CT. J Nucl Med 63, 1027\u20131032 (2022)","journal-title":"J Nucl Med"},{"key":"4138_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.compbiomed.2014.04.014","volume":"50","author":"B Foster","year":"2014","unstructured":"B. Foster, U. Bagci, A. Mansoor, Z. Xu, D.J. Mollura, A review on segmentation of positron emission tomography images. Comput Biol Med 50, 76\u201396 (2014)","journal-title":"Comput Biol Med"},{"key":"4138_CR17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"A. Gafita, L. Djaileb, I. Rauscher, W.P. Fendler, B. Hadaschik, S.P. Rowe et al. Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology 308, e222148 (2023)","journal-title":"Radiology"},{"key":"4138_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"A. Gafita, M. Bieth, M. Kr\u00f6nke, G. Tetteh, F. Navarro, H. Wang et al. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET\/CT. J Nucl Med 60, 1277\u20131283 (2019)","journal-title":"J Nucl Med"},{"key":"4138_CR19","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"R.L. Wahl, H. Jacene, Y. Kasamon, M.A. Lodge, From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50, 122S\u2013150SS (2009). Suppl 1","journal-title":"J Nucl Med"},{"key":"4138_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2967\/jnumed.123.265987","volume":"65","author":"M Mileva","year":"2024","unstructured":"M. Mileva, G. Marin, H. Levillain, C. Artigas, C. Van Bogaert, C. Marin et al. Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. J Nucl Med 65, 236\u2013244 (2024)","journal-title":"J Nucl Med"},{"key":"4138_CR21","doi-asserted-by":"crossref","unstructured":"Maccauro M., Cuomo M., Bauckneht M., Bagnalasta M., Mazzaglia S., Scalorbi F., et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [(177)Lu]Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2024;52:291\u2013304.","DOI":"10.1007\/s00259-024-06863-y"},{"key":"4138_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2967\/jnumed.123.267023","volume":"65","author":"K Hebert","year":"2024","unstructured":"K. Hebert, L. Santoro, M. Monnier, F. Castan, I. Berkane, E. Ass\u00e9nat et al. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. J Nucl Med 65, 923\u2013930 (2024)","journal-title":"J Nucl Med"},{"issue":"1","key":"4138_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12020-020-02341-1","volume":"70","author":"C Chiapponi","year":"2020","unstructured":"C. Chiapponi, N. L\u00fcrssen, B. Cremer, R. Wahba, U. Drebber, M. Faust et al. Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience. Endocrine 70(1), 187\u2013193 (2020). Oct","journal-title":"Endocrine"},{"key":"4138_CR24","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1097\/RLU.0000000000002480","volume":"44","author":"M Maccauro","year":"2019","unstructured":"M. Maccauro, G.A. Follacchio, C. Spreafico, J. Coppa, E. Seregni Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor. Clin Nucl Med 44, e286\u2013e288 (2019)","journal-title":"Clin Nucl Med"},{"key":"4138_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2967\/jnumed.111.090373","volume":"52","author":"S Ezziddin","year":"2011","unstructured":"S. Ezziddin, A. Sabet, F. Heinemann, C.J. Yong-Hing, H. Ahmadzadehfar, S. Guhlke et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med 52, 1197\u20131203 (2011)","journal-title":"J Nucl Med"},{"key":"4138_CR26","first-page":"OP2300789","volume":"27","author":"R Halperin","year":"2024","unstructured":"R. Halperin, A. Tirosh, Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors. JCO Oncol Pract 27, OP2300789 (2024)","journal-title":"JCO Oncol Pract"},{"key":"4138_CR27","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1007\/s00259-024-06767-x","volume":"51","author":"V Santoro-Fernandes","year":"2024","unstructured":"V. Santoro-Fernandes, B. Schott, A. Deatsch, Q. Keigley, T. Francken, R. Iyer et al. Models using comprehensive, lesion-level, longitudinal [(68)Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [(177)Lu]Lu-DOTA-TATE. Eur J Nucl Med Mol Imaging 51, 3428\u20133439 (2024)","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04138-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:21:39Z","timestamp":1740129699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04138-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["4138"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04138-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and was approved by local Institutional Review Board (IRB-2024-24).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}